Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03585465
Title Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Centre Oscar Lambret
Indications

rhabdomyosarcoma

low grade glioma

Ewing sarcoma

neuroblastoma

central nervous system embryonal carcinoma

high grade ependymoma

Therapies

Capecitabine + Cyclophosphamide + Nivolumab + Vinblastine

Capecitabine + Cyclophosphamide + Vinblastine

Cyclophosphamide + Nivolumab + Vinblastine

Capecitabine + Nivolumab

Age Groups: adult | child
Covered Countries


No variant requirements are available.